B-cell acute lymphoblastic leukemia,B-ALL
Conditions
Interventions
Trail group:no
Sponsors
HenanCancerHospital
Eligibility
Sex/Gender
All
Age
15 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) According to the WHO diagnostic criteria, patients diagnosed with B-ALL (leukemia cells >= 20% in newly diagnosed patients, leukemia cells >= 5% in relapsed and refractory patients, or patients with CR but positive MRD) through MICM testing; Leukemia cells >= 50% indicate high burden, while Leukemia cells = 15 years old, and there is no age limit for relapsed and refractory patients; 3) The patient was treated with CD3CD19 bispecific antibodies; 4) Fully understand and voluntarily sign a written informed consent form (ICF); 5) ECOG score 0-3 scores; 6) Expected survival time >= 3 months; 7) Liver function: Total bilirubin = 30mL/min; 9) Patients who sign the informed consent form must have the ability to understand and be willing to participate in this study, and must also sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1) T cell ALL; 2) MRD negative B cell ALL; 3) Mature B-cell leukemia/lymphoma, B-lymphocyte lymphoma, isolated extramedullary diseases; 4) Acute mixed cell leukemia; 5) Combined central nervous system leukemia; 6) HIV infection, positive HBV-DNA or HCV-RNA; 7) Patients with heart failure level 2 or above and those deemed unsuitable for inclusion by other researchers; 8) Pregnant, lactating, or female patients who have fertility but have not taken contraceptive measures; 9) Individuals with uncontrollable neurological, psychiatric, psychiatric, or cognitive impairments may limit their understanding, execution, and compliance with informed consent forms.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transcriptome and TCR repertoire of CD3+T cells; | — |
Countries
China
Contacts
Public ContactQingsong Yin
HenanCancerHospital
Outcome results
None listed